Benefit of adjuvant BMA (bone modifying agents, meaning bisphosphonates and denosumab) in eBC
Expert: Michael Gnant, Comprehensive Cancer Center Vienna, Vienna, Austria
Questions:
1.What is the recommendation for use of bisphosphonates in eBC? Which agents? How long? To which patients?
2.What is the benefit of adjuvant bisphosphonates in eBC (breast cancer - related outcomes and other benefit)?
3.What is the recommendation for use of denosumab in eBC?
4.What are the data to support these recommendations for practice?
Create your
podcast in
minutes
It is Free